Life Sciences Tools and Services
Company Overview of inVentiv Health Inc.
inVentiv Health Inc. provides value-added services to the pharmaceutical and life sciences industries in the U.S. and internationally. The company supports a range of clinical development, communications, and commercialization activities critical to developing new drug products and medical devices. Its inVentiv Clinical segment provides services related to permanent placement, clinical staffing, data collection and management, and functional outsourcing. The inVentiv Communications segment furnishes advertising, communications, and other functionally related services. InVentiv Commercial provides commercialization services, including outsourced product commercialization programs; patient sup...
1 Van de Graaff Drive
Burlington, MA 01803
Founded in 1996
Key Executives for inVentiv Health Inc.
Executive Chairman and Chief Executive Officer
President of Smith Hanley Companies and Chief Executive Officer of Smith Hanley Companies
Chief Executive Officer of i3 Organization
Chief Executive Officer of Campbell Alliance
Compensation as of Fiscal Year 2014.
inVentiv Health Inc. Key Developments
inVentiv Health And Aprecia Pharmaceuticals Form Innovative Partnership to Commercialize Aprecia's Unique Technology Platform
Jun 4 14
inVentiv Health and Aprecia Pharmaceuticals announced an exclusive sales and marketing alliance. This partnership will launch the Aprecia brand, as well as provide comprehensive commercialization of Aprecia's pioneering technology platform and initial pharmaceutical products. Aprecia is the first and only pharmaceutical company offering the proprietary ZipDose(R) product platform using three-dimensional printing (3DP) technology to create fast-melt products. These products promise to change how patients experience taking their medicine by making drugs easier to administer and swallow. Aprecia has completed clinical work and expects to file its first New Drug Application with the Food and Drug Administration (FDA) in the second half of 2014. inVentiv Health has directly supported the development and/or commercialization of 60% of all drugs approved by the FDA in the last 5 years. By partnering with inVentiv, Aprecia gains access to the industry's only full commercialization outsourcing organization. Under the terms of the agreement, inVentiv will partner with Aprecia as its exclusive provider of comprehensive commercialization services and will share in the success of the commercialization efforts. inVentiv will invest time and materials to launch Aprecia and to commercialize its products in exchange for a negotiated royalty from future sales. inVentiv's services include: sales teams and sales training, strategic and tactical market access services, non-personal promotion, advertising, public relations, adherence services, and full management of the commercialization teams.
Orexo US, Inc. and inVentiv Health Announce Partnership for the Commercialization of Zubsolv in the US
May 21 14
Orexo AB announced a new partnership between Orexo US Inc. and inVentiv Health for the commercialization of Zubsolv in the US. The new partnership agreement replaces existing contracts and will become effective July 1, 2014 and has a three year term. In the new partnership, Orexo takes the leadership and control of all commercial functions to ensure the efficient and agile governance of the commercialization of Zubsolv. Consequently Orexo will directly employ the sales managers and take over leadership and day to day management of field-based promotional activities. The new partner inVentiv Health will take responsibility of employing and supporting the individual sales representatives. The new partnership calls for Orexo to cover direct sales force expenses from inVentiv Health.
inVentiv Health Inc. Appoints Michael A. Griffith as Executive Vice President
Mar 10 14
inVentiv Health Inc. announced that the appointment of Michael A. Griffith as Executive Vice President. In this capacity, Griffith will head the company's Commercial and Consulting businesses and report to the company Health CEO Paul Meister. Most recently, Griffith was the Chief Executive Officer of Laureate Biopharma.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 15, 2014